Table 1.

CXCL9 expression in human tumor biopsies treated ex vivo with galectin antagonists.

Tumor code	Tumor type	Untreated (*)	LacNAc	IFNγ	IFNγ + galectins antagonists
					LacNAc	GM-CT-01	αGal3 mIgG1	αGal3 ratIgG
13-121	Neuroendocrina	1 (3)	51	317	281	N/A	N/A	N/A
14-031	Adenocarcinoma	1 (12)	1	5	2	2	N/A	N/A
13-212	Adenocarcinoma	1 (33)	15	7	82	N/A	N/A	N/A
14-286	Renal carcinoma	1 (67)	N/A	36	91		242	N/A
14-581	Pancreatic carcinoma	1 (77)	29	112	392	251	31	8
13-248	Adenocarcinoma	1 (78)	2	1	3	N/A	N/A	N/A
13-480	Adenocarcinoma	1 (89)	0	2	73	12	N/A	N/A
15-426	Uterine carcinoma	1 (139)	2	2	5	10	1	1
12-477	Adenocarcinoma	1 (168)	1	1	2	N/A	N/A	N/A
13-298	Adenoma	1 (193)	2	2	5	N/A	N/A	N/A
13-568	Hepatoadenoma	1 (268)	1	5	11	9	N/A	N/A
LB-3422	Melanoma	1 (379)	0	1	16	2	N/A	N/A
14-063	Adenocarcinoma	1 (399)	5	7	14	14	N/A	N/A
14-583	Adenocarcinoma	1 (406)	N/A	2	7	2	4	8
15-427	Adenocarcinoma	1 (489)	1	3	3	2	3	2
15-228	Sarcoma	1 (972)	2	98	193	195	116	138
14-187	Rectal adenocarcinoma	1 (1065)	1	1	5	3	N/A	N/A
13-420	Lymphoma B diffuse	1 (1278)	2	2	2	N/A	N/A	N/A
14-526	Renal carcinoma	1 (1287)	2	3	3	3	1	2
13-454	Adenocarcinoma	1 (1287)	1	2	1	N/A	N/A	N/A
12-529	Hepatoblastoma	1 (1628)	4	3	8	N/A	N/A	N/A
14-239	Renal carcinoma	1 (3321)	1	2	2	1	1	N/A
12-549	Leiomyoma	1 (8056)	14	5	33	40	N/A	N/A

Fold induction CXCL9 values using HPRT-1 as a reference gene and with respect to the untreated condition (2^−ΔΔCt). For the untreated condition, CXCL9 mRNA levels normalized to HPRT-1 (10³ × 2^−ΔCt) are indicated in brackets. Human biopsies were treated for 6 h with IFNγ (50 ng ml⁻¹), LacNAc (10 mM), GM-CT-01 (100 μg ml⁻¹), and/or anti-galectin-3 antibodies (10 μg ml⁻¹)

N/A no available data